Opendata, web and dolomites

MPT system

Innovative, cost-effective, ultra-compact MRI-guided therapy system for diagnosis and immediate treatment of Parkinson's Disease

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MPT system project word cloud

Explore the words cloud of the MPT system project. It provides you a very rough idea of what is the project "MPT system" about.

competitors    feasibility    disease    complications    saving    investment    peer    particle    sized    spain    surgical    electrical    markets    compact    2m    presented    valuable    labor    currently    nanoparticles    shielding    tremors    primarily    2050    italy    performed    ip    ageing    brain    chain    breakthroughs    space    size    fast    setup    hospitals    serious    guided    deep    hemorrhages    placement    weighs    invasive    anymore    consisting    treatments    neuroparticle    conjunction    supply    kg    germany    patients    people    stimulation    drug    published    treatment    conferences    continues    preliminary    forecast    save    dbs    procedure    requiring    contacts    mpt    additional    parkinson    medication    regions    therapy    head    stiffness    initial    estimates    machine    responsible    sell    movement    walking    population    afflicted    double    tested    insure    perfectly    magnetic    clinical    trials    pd    image    private    installation    journals    incidence    relative    patents    scientific    updated    purchase    infections    medical    trouble    ultra    disorders    excellent    technological   

Project "MPT system" data sheet

The following table provides information about the project.

Coordinator
NEUROPARTICLE EU LIMITED 

Organization address
address: UNIT 6 QUEENS YARD, WHITE POST LANE
city: LONDON
postcode: E9 5EN
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website https://neuroparticle.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-06-01   to  2019-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    NEUROPARTICLE EU LIMITED UK (LONDON) coordinator 50˙000.00

Map

 Project objective

Currently, there are 1.2M people afflicted by Parkinson’s disease (PD) only in EU and the incidence is forecast to double by 2050 primarily as a result of the ageing population. They require high invasive treatments when drug therapy and early medication are not effective anymore. Then, Deep Brain Stimulation (DBS) is the most commonly performed surgical treatment for Parkinson's patients, consisting in electrical stimulation of the deep regions of the brain responsible for movement disorders such tremors, stiffness and trouble walking. However, this treatment is highly-invasive and may lead to serious complications like hemorrhages and infections. Neuroparticle developed the Magnetic Particle Therapy (MPT), an ultra-compact, low-cost and non-invasive system for DBS in PD treatment. This stimulation is performed by image-guided placement of magnetic nanoparticles into the brain. The Neuroparticle’s system has been tested in various pre-clinical trials with excellent results published on peer- reviewed medical journals and presented at scientific conferences. This technological breakthroughs also enables meaningful reduction in size as it weighs only 90 kg and is perfectly head-sized (no shielding needed), saving hospitals valuable space and requiring less initial investment on setup labor. Finally, preliminary cost estimates show that the Neuroparticle’s system will allow hospitals to save up to 2/3 on cost of purchase and installation relative to competitors. During the Phase 1 feasibility assessment, in conjunction with partners, Neuroparticle will identify specific private hospitals to sell to. Target markets of Germany, Italy and Spain will be sized and contacts established. A supply chain procedure will be established in order to insure fast delivery for machine setup. As R&D continues, additional IP will be updated via patents.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MPT SYSTEM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MPT SYSTEM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

RDNA (2019)

Empowering New Venture Growth - RDNA

Read More  

MEDIVAC (2019)

Machine learning software to design personalized neoantigen vaccines tailored to specific vaccine delivery systems

Read More  

Totem Spoon (2019)

Interactive Digital Signage with emotional intelligence for smart cities

Read More